Answers are grounded in this paper and cite their sources.
In early phases of the drug discovery process, evaluating the off-target pharmacology of a candidate drug is important when considering potential safety risks. Such off-target liabilities are most commonly evaluated using panels of in vitro pharmacology assays with strong association to well-defined toxicological events. In addition to in vitro panels, preliminary in silico evaluation is emerging as a valuable approach to support identification of potential off-target hits, even prior to synthesis of chemical material. To ascertain the utility of in silico target profiling, the predictive performance of a proprietary in silico predictive tool was evaluated against an in-house data set of 94 compounds with associated in vitro panel data, including binding inhibition and functional agonism/antagonism. Of the compounds tested, the primary target was predicted with 35% sensitivity. However, the sensitivity to predict the primary target decreased to 16% for a subset of compounds not reported within the Chemical Abstracts Service registry. For the known off-target hits for all tested compounds, the value of sensitivity was 16% for binding assays and 23% for functional assays. To better understand the applicability of the in silico off-target prediction, we performed in vitro binding assays, to evaluate five additional off-targets that were predicted by in silico but not covered by our standard off-target binding or functional panels. Although no new off-target hit was identified through this campaign, as technologies evolve, the in silico predictions could provide valuable insights to identify potential off-targets and mechanistic insights on target organ toxicities caused by compounds in in vivo studies.
No takes yet. Share an insight, caveat, or question.
Takai et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: